Century Therapeutics, Inc. (IPSC): Price and Financial Metrics
IPSC Price/Volume Stats
| Current price | $0.56 | 52-week high | $3.46 |
| Prev. close | $0.57 | 52-week low | $0.34 |
| Day low | $0.55 | Volume | 752,000 |
| Day high | $0.57 | Avg. volume | 592,803 |
| 50-day MA | $0.52 | Dividend yield | N/A |
| 200-day MA | $1.03 | Market Cap | 48.51M |
IPSC Stock Price Chart Interactive Chart >
Century Therapeutics, Inc. (IPSC) Company Bio
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT or CAR-iNK candidate targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia. The company was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
IPSC Latest News Stream
| Event/Time | News Detail | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
IPSC Price Returns
| 1-mo | 7.32% |
| 3-mo | -14.56% |
| 6-mo | -63.16% |
| 1-year | -81.46% |
| 3-year | -93.66% |
| 5-year | N/A |
| YTD | -44.55% |
| 2024 | -69.58% |
| 2023 | -35.28% |
| 2022 | -67.65% |
| 2021 | N/A |
| 2020 | N/A |